We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
XELJANZ tofacitinib 1mg/mL oral solution bottle (Germany)
Section 19A approved medicine
XELJANZ tofacitinib 1mg/mL oral solution bottle (Germany)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
XELJANZ tofacitinib (as citrate) 1mg/mL oral solution bottle - ARTG 386772
Indication(s)
The treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.
Images
